95 completed. 95 Phase 3, 8 Phase 2.
By phase and status
Follow Urticaria: new trials by email Literature Review of Urticaria trials Research Report on Urticaria
Trials (filtered) newest first · largest first
All 95 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II
KVD900 150 mg, KVD900 300 mg, KVD900 600 mg - Hereditary Angioedema | Phase 3 | Completed | 36 | 2024-08-01 | 2026-08-05 |
To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria
CMAB007, Xolair - Chronic Spontaneous Urticaria | Phase 3 | Completed | 392 | 2024-06-18 | 2026-10-02 |
Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Deucrictibant, Placebo - Hereditary Angioedema, Hereditary Angioedema Type I | Phase 3 | Completed | 134 | 2024-02-26 | 2025-11-21 |
Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria
Omalizumab Injection, Xolair Prefilled Syringe - Chronic Idiopathic Urticaria | Phase 3 | Completed | 600 | 2023-08-15 | 2025-02-05 |
CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema
CSL312 - Hereditary Angioedema (HAE) | Phase 3 | Completed | 22 | 2023-05-30 | 2026-06-02 |
A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.
LOU064 - Chronic Spontaneous Urticaria | Phase 3 | Completed | 144 | 2023-04-05 | 2025-10-16 |
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
KVD900 600 mg, KVD900 300 mg - Hereditary Angioedema | Phase 3 | Completed | 145 | 2022-10-24 | 2026-06-05 |
PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
KVD900 600 mg, Drug: KVD900 300 mg - Hereditary Angioedema | Phase 3 | Completed | 11 | 2022-10-24 | 2026-06-08 |
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)
Dupilumab - Chronic Spontaneous Urticaria | Phase 3 | Completed | 15 | 2022-08-25 | 2025-11-25 |
A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)
Lanadelumab - Hereditary Angioedema (HAE) | Phase 3 | Completed | 20 | 2022-06-22 | 2024-12-13 |
A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
Placebo, KVD900 600 mg, KVD900 300 mg - Hereditary Angioedema | Phase 3 | Completed | 136 | 2022-02-22 | 2025-05-02 |
A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines
LOU064 - Chronic Spontaneous Urticaria | Phase 3 | Completed | 71 | 2022-01-15 | 2025-04-08 |
OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)
Donidalorsen, Placebo - Hereditary Angioedema | Phase 3 | Completed | 91 | 2021-12-03 | 2025-03-06 |
A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines
LOU064 (blinded), Placebo, LOU064 (open-label) - Chronic Spontaneous Urticaria | Phase 3 | Completed | 455 | 2021-12-01 | 2025-04-08 |
A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines
LOU064 25 mg (b.i.d), Placebo, LOU064 25 mg (b.i.d) as a tablet. - Chronic Spontaneous Urticaria | Phase 3 | Completed | 470 | 2021-11-30 | 2025-04-08 |
Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria
TEV-45779, XOLAIR® Injection - Chronic Urticaria | Phase 3 | Completed | 608 | 2021-08-30 | 2025-10-07 |
Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks
CSL312 - Hereditary Angioedema | Phase 3 | Completed | 171 | 2021-03-29 | 2026-06-02 |
Expanded Access Program With Lanadelumab for Japanese People With Hereditary Angioedema
TAK-743 300 mg - Hereditary Angioedema | Phase 3 | Completed | 12 | 2021-02-10 | 2023-06-26 |
A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor
Lanadelumab - Angioedema | Phase 3 | Completed | 73 | 2021-02-05 | 2024-06-17 |
CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks
CSL312, Placebo - Hereditary Angioedema | Phase 3 | Completed | 64 | 2021-01-27 | 2023-06-29 |
Showing 20 of 95. Sign in to see all of them.
Narrower conditions
Angioedemas, Hereditary (43) · Chronic Urticaria (28) · Angioedema (10) · Cryopyrin-Associated Periodic Syndromes (8) · Hereditary Angioedema Types I and II (5) · Hypersensitivity (5) · Multiple Pterygium Syndrome, Autosomal Dominant (5) · Rhinitis, Allergic (3) · Acquired angioedema (2) · Bronchiolitis Obliterans Syndrome (2) · Cold Urticaria (2) · Genetic Diseases, Inborn (2) · Hypersensitivity, Immediate (2) · Immune System Diseases (2)
Broader conditions
Skin and Connective Tissue Diseases (95) · Skin Diseases (94) · Hypersensitivity, Immediate (93) · Immune System Diseases (93) · Skin Diseases, Vascular (93) · Hypersensitivity (90) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (51) · Cardiovascular Diseases (50) · Vascular Diseases (50) · Genetic Diseases, Inborn (49) · Hereditary Complement Deficiency Diseases (43) · Immunologic Deficiency Syndromes (43) · Primary Immunodeficiency Diseases (43) · Angioedema (40)
Interventions
Omalizumab (14) · Complement C1 Inhibitor Protein (11) · lanadelumab (8) · canakinumab (7) · icatibant (7) · levocetirizine (6) · Sodium Chloride (5) · desloratadine (4) · remibrutinib (4) · sebetralstat (4) · berotralstat (3) · bilastine (3) · dupilumab (3) · ecallantide (3) · ligelizumab (3)
Sponsors
Shire (21) · Novartis Pharmaceuticals (15) · CSL Behring (7) · BioCryst Pharmaceuticals (4) · KalVista Pharmaceuticals, Ltd. (4) · Takeda (4) · Charite University, Berlin, Germany (3) · Genentech, Inc. (3) · Organon and Co (3) · Pharming Technologies B.V. (3) · Sanofi (3) · UCB Pharma (3) · Novartis (2) · Prothya Biosolutions (2) · AO GENERIUM (1)
Countries
United States (54) · Germany (41) · Canada (37) · Spain (29) · France (27) · Japan (23) · Italy (22) · United Kingdom (22) · Hungary (21) · Israel (19) · Poland (17) · Australia (15) · Romania (15) · Netherlands (14) · Argentina (11)
Top investigators
M. M. Levi, Prof. Dr. (2) · Marcus Maurer, MD (2) · Anurag Relan, MD (1) · Baek-Hwan Cho, MD., PhD (1) · Bruce Zuraw, MD (1)
Results publications
PMID 36326435, PMID 20818886, PMID 23312695, PMID 23548529, PMID 23878046, PMID 24712435, PMID 26054553, PMID 27424128, PMID 27540466, PMID 27939380, PMID 28390587, PMID 29655772, PMID 36408587, PMID 42159953, PMID 20818888, PMID 20819318, PMID 20920772, PMID 21130380, PMID 22765833, PMID 22856635, PMID 23484892, PMID 23548526, PMID 23987198, PMID 28284978, PMID 31161734, PMID 36153561, PMID 37028510, PMID 38008109, PMID 39193419, PMID 40043237, PMID 40380356, PMID 40469312, PMID 40886933, PMID 42268494, PMID 42297099, PMID 17073887, PMID 18668535, PMID 19494217, PMID 19767078, PMID 19860762, PMID 20674826, PMID 20818887, PMID 21195947, PMID 21859692, PMID 21884533, PMID 22123383, PMID 22136279, PMID 22152723, PMID 22192966, PMID 22856636
NIH funding
2015 (3), 2018 (3), 2019 (3), 2004 (2), 2009 (2), 2014 (2), 2008 (1)